From Nelson’s Syndrome to Corticotroph Tumor Progression Speed: An Update

Abstract

Since the first description of Nelson syndrome 60 years ago, the way to consider corticotroph pituitary neuroendocrine tumors (PitNETs) after bilateral adrenalectomy has evolved. Today, it is globally acknowledged that only a subset of corticotroph PitNETs is aggressive.

After adrenalectomy, corticotroph tumor progression (CTP) occurs in about 30 to 40% of patients during a median follow-up of 10 years. When CTP occurs, various CTP speeds (CTPS) can be observed. Using simple metrics in patients with CTP, CTPS was reported to vary from a few millimeters to up to 40 mm per year. Rapid CTPS/ Nelson’s syndrome was associated with more severe Cushing’s disease, higher adrenocorticotropic hormone (ACTH) in the year following adrenalectomy, and higher Ki67 on pituitary pathology. Complications such as apoplexy, cavernous syndrome, and visual defects were associated with higher CTPS. During follow-up, early morning ACTH, absolute variations properly reflected CTPS. Finally, CTPS was not higher after than before adrenalectomy, suggesting that cortisol deprivation after adrenalectomy does not impact CTPS in a majority of patients.

Taken together, rapid CTPS/ Nelson’s syndrome probably reflects the intrinsic aggressiveness of some corticotroph PitNETs. The precise molecular mechanisms related to corticotroph PitNET aggressiveness remain to be deciphered. Regular MRIs combined with intermediate morning ACTH measurements probably provide a reliable way to detect early and manage fast-growing tumors and, therefore, limit the complications.

Keywords

PitNET - Nelson - Cushing - adrenalectomy

Publication History

Received: 21 April 2024
Received: 28 June 2024

Accepted: 02 July 2024

Accepted Manuscript online:
03 July 2024

Article published online:
30 August 2024

• References

• 1 Alexandraki KI, Kaltsas GA, Isidori AM. et al. Long-term remission and recurrence rates in Cushing’s disease: Predictive factors in a single-centre study. Eur J Endocrinol 2013; 168: 639-648
• 2 Bertagna X. Management of endocrine disease: Can we cure Cushing’s disease? A personal view. Eur J Endocrinol 2018; 178: R183-R200
• 3 Platt R. Two essays on the practice of medicine. Lancet 1947; 2: 305-307
• 4 Bergthorsdottir R, Leonsson-Zachrisson M, Odén A. et al. Premature mortality in patients with Addison’s disease: A population-based study. J Clin Endocrinol Metab 2006; 91: 4849-4853
• 5 Smith PW, Turza KC, Carter CO. et al. Bilateral adrenalectomy for refractory Cushing disease: A safe and definitive therapy. J Am Coll Surg 2009; 208: 1059-1064
• 6 Ritzel K, Beuschlein F, Mickisch A. et al. Clinical review: Outcome of bilateral adrenalectomy in Cushing’s syndrome: A systematic review. J Clin Endocrinol Metab 2013; 98: 3939-3948
• 7 Morris LF, Harris RS, Milton DR. et al. Impact and timing of bilateral adrenalectomy for refractory ACTH-dependent Cushing’s syndrome. Surgery 2013; 154: 1174-1184
• 8 Nelson DH, Meakin JW, Dealy JB. et al. ACTH-producing tumor of the pituitary gland. N Engl J Med 1958; 259: 161-164
• 9 Guiot J, Rougerie J, Fourestier M. et al. Intracranial endoscopic explorations. Presse Med 1963; 71: 1225-1228
• 10 Hardy J. Excision of pituitary adenomas by trans-sphenoidal approach. Union Med Can 1962; 91: 933-945
• 11 Bertagna X, Guignat L, Groussin L. et al. Cushing’s disease. Best Pract Res Clin Endocrinol Metab 2009; 23: 607-623
• 12 Zada G. Diagnosis and multimodality management of Cushing’s disease: A practical review. Int J Endocrinol 2013; 2013: 893781
• 13 Lindsay JR, Shanmugam VK, Oldfield EH. et al. A comparison of immunometric and radioimmunoassay measurement of ACTH for the differential diagnosis of Cushing’s syndrome. J Endocrinol Invest 2006; 29: 983-988
• 14 Corrigan DF, Schaaf M, Whaley RA. et al. Selective venous sampling to differentiate ectopic ACTH secretion from pituitary Cushing’s syndrome. N Engl J Med 1977; 296: 861-862
• 15 Isidori AM, Kaltsas GA, Mohammed S. et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 2003; 88: 5299-5306
• 16 Bertagna X, Guignat L. Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 2013; 98: 1307-1318
• 17 Assié G, Bahurel H, Bertherat J. et al. The Nelson’s syndrome... revisited. Pituitary 2004; 7: 209-215
• 18 Assié G, Bahurel H, Coste J. et al. « Corticotroph tumor progression after adrenalectomy in Cushing’s Disease: A reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 2007; 92: 172-179
• 19 Valassi E, Castinetti F, Ferriere A. et al. Corticotroph tumor progression after bilateral adrenalectomy: Data from ERCUSYN. Endocr Relat Cancer 2022; 29: 681-691
• 20 Papakokkinou E, Piasecka M, Carlsen HK. et al. Prevalence of Nelson’s syndrome after bilateral adrenalectomy in patients with cushing’s disease: A systematic review and meta-analysis. Pituitary 2021; 24: 797-809
• 21 Bessiène L, Moutel S, Lataud M. et al. Corticotroph tumor progression speed after adrenalectomy. Eur J Endocrinol 2022; 187: 797-807
• 22 Pérez-Rivas LG, Theodoropoulou M, Puar TH. et al. Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson’s tumor. Eur J Endocrinol 2018; 178: 57-63
• 23 Asa SL, Casar-Borota O, Chanson P. et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): An International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017; 24: C5-C8
• 24 Asa SL, Osamura RY, Mete O. et al. WHO classification of tumours of endocrine organs, 5th ed.. Lyon, France: International Agency for Research on Cancer; 2022
• 25 Lopes MBS, Asa SL, Kleinschmidt-DeMasters BK. et al. Pituitary adenoma/pituitary neuroendocrine tumours. In: WHO Classification of Tumours: Central Nervous System Tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 6. 2021
• 26 Villa C, Baussart B, Assié G. et al. The World Health Organization classifications of pituitary neuroendocrine tumours: A clinico-pathological appraisal. Endocr Relat Cancer 2023; 30: e230021
• 27 Mete O, Wenig BM. Update from the 5th Edition of the World Health Organization classification of head and neck tumors: Overview of the 2022 WHO classification of head and neck neuroendocrine neoplasms. Head Neck Pathol 2022; 16: 123-142
• 28 Louis DN. Introduction to CNS tumours. In: WHO classification of tumours: Central nervous system tumours, 5th ed.. Lyon, France: International Agency for Research on Cancer; 6.
• 29 Raverot G, Burman P, McCormack A. et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018; 178: G1-G24
• 30 Burman P, Trouillas J, Losa M. et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 2022; 187: 593-605
• 31 Raverot G, Ilie MD, Lasolle H. et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 2021; 17: 671-684
• 32 Heaney AP. Clinical review: Pituitary carcinoma: Difficult diagnosis and treatment. J Clin Endocrinol Metab 2011; 96: 3649-3660
• 33 Trouillas J, Roy P, Sturm N. et al. A new prognostic clinicopathological classification of pituitary adenomas: A multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013; 126: 123-135
• 34 Raverot G, Dantony E, Beauvy J. et al. Risk of recurrence in pituitary neuroendocrine tumors: A prospective study using a five-tiered classification. J Clin Endocrinol Metab 2017; 102: 3368-3374
• 35 Sahakian N, Appay R, Resseguier N. et al. Real-life clinical impact of a five-tiered classification of pituitary tumors. Eur J Endocrinol 2022; 187: 893-904
• 36 Asioli S, Righi A, Iommi M. et al. Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: Retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 2019; 180: 127-134
• 37 Woo YS, Isidori AM, Wat WZ. et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90: 4963-4969
• 38 Farrell WE, Coll AP, Clayton RN. et al. Corticotroph carcinoma presenting as a silent corticotroph adenoma. Pituitary 2003; 6: 41-47
• 39 Melcescu E, Gannon AW, Parent AD. et al. Silent or subclinical corticotroph pituitary macroadenoma transforming into Cushing disease: 11-year follow-up. Neurosurgery 2013; 72: E144-E146
• 40 Brown RL, Wollman R, Weiss RE. Transformation of a pituitary macroadenoma into to a corticotropin-secreting carcinoma over 16 years. Endocr Pract 2007; 13: 463-471
• 41 Fang H, Tian R, Wu H. et al. Cushing disease after treatment of nonfunctional pituitary adenoma: A case report and literature review. Medicine (Baltimore) 2015; 94: e2134
• 42 Rotman LE, Vaughan TB, Hackney JR. et al. Long-term survival following transformation of an adrenocorticotropic hormone secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma: Case report. World Neurosurg 2018;
• 43 Kakade HR, Kasaliwal R, Khadilkar KS. et al. Clinical, biochemical and imaging characteristics of Cushing’s macroadenomas and their long-term treatment outcome. Clinical Endocrinology 2014; 81: 336-342
• 44 Minniti G, Brada M. Radiotherapy and radiosurgery for Cushing’s disease. Arq Bras Endocrinol Metabol 2007; 51: 1373-1380
• 45 Estrada J, Boronat M, Mielgo M. et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 1997; 336: 172-177
• 46 Castinetti F, Nagai M, Morange I. et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 2009; 94: 3400-3407
• 47 Jagannathan J, Sheehan JP, Pouratian N. et al. Gamma knife surgery for Cushing’s disease. J Neurosurg 2007; 106: 980-987
• 48 Trifiletti DM, Xu Z, Dutta SW. et al. Endocrine remission after pituitary stereotactic radiosurgery: Differences in rates of response for matched cohorts of Cushing disease and acromegaly patients. Int J Radiat Oncol Biol Phys 2018; 101: 610-617
• 49 Castinetti F, Guignat L, Giraud P. et al. Ketoconazole in Cushing’s disease: Is it worth a try?. J Clin Endocrinol Metab 2014; 99: 1623-1630
• 50 Daniel E, Aylwin S, Mustafa O. et al. Effectiveness of metyrapone in treating Cushing’s syndrome: A retrospective multicenter study in 195 patients. J Clin Endocrinol Metab 2015; 100: 4146-4154
• 51 Baudry C, Coste J, Bou Khalil R. et al. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol 2012; 167: 473-481
• 52 Fontaine-Sylvestre C, Létourneau-Guillon L, Moumdjian RA. et al. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing’s disease. Pituitary 2021; 24: 207-215
• 53 Reincke M, Sbiera S, Hayakawa A. et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 2015; 47: 31-38
• 54 Albani A, Sbiera S, Hayakawa A. et al. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Endocr Relat Cancer 2022; 29: 503-511
• 55 Treppiedi D, Marra G, Di Muro G. et al. P720R USP8 mutation is associated with a better responsiveness to pasireotide in ACTH-secreting PitNETs. Cancers (Basel) 2022; 14: 2455
• 56 Perez-Rivas LG, Simon J, Albani A. et al. TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome. Acta Neuropathol Commun 2022; 10: 139
• 57 Casar-Borota O, Boldt HB, Engström BE. et al. Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab 2021; 106: 1183-1194
• 58 Ho KKY, Kaiser UB, Chanson P. et al. Pituitary adenoma or neuroendocrine tumour: The need for an integrated prognostic classification. Nat Rev Endocrinol 2023; 19: 671-678
• 59 Ho KKY, Fleseriu M, Wass J. et al. A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis. Lancet Diabetes Endocrinol 2024; 12: 209-214
• 60 Lloyd R, Osamura R, Kloppel G. et al. WHO Classification of Tumours of Endocrine Organs. 4th ed. WHO-OMS; 2017. Available on: https://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4010
• 61 Hansen TM, Batra S, Lim M. et al. Invasive adenoma and pituitary carcinoma: A SEER database analysis. Neurosurg Rev 2014; 37: 279-285
• 62 Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT. et al. Pituitary carcinoma: A clinicopathological review. Neurosurgery 2005; 56: 1066-1074
• 63 Sansur CA, Oldfield EH. Pituitary carcinoma. Semin Oncol 2010; 37: 591-593
• 64 Ragel BT, Couldwell WT. Pituitary carcinoma: A review of the literature. Neurosurg Focus 2004; 16: E7
• 65 Holthouse DJ, Robbins PD, Kahler R. et al. Corticotroph pituitary carcinoma: Case report and literature review. Endocr Pathol 2001; 12: 329-341
• 66 Kemink SA, Wesseling P, Pieters GF. et al. Progression of a Nelson’s adenoma to pituitary carcinoma; a case report and review of the literature. J Endocrinol Invest 1999; 22: 70-75
• 67 Gaffey TA, Scheithauer BW, Lloyd RV. et al. Corticotroph carcinoma of the pituitary: A clinicopathological study. Report of four cases. J Neurosurg 2002; 96: 352-360
• 68 Roncaroli F, Scheithauer BW, Young WF. et al. Silent corticotroph carcinoma of the adenohypophysis: A report of five cases. Am J Surg Pathol 2003; 27: 477-486
• 69 McKay LI, Cidlowski JA. Corticosteroids in the treatment of neoplasms. Holland-Frei Cancer Medicine. 6th ed. 2003 Available on: https://www.ncbi.nlm.nih.gov/books/NBK13383/
• 70 Xing K, Gu B, Zhang P. et al. Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: An insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunol 2015; 16
• 71 Van Aken MO, Pereira AM, van den Berg G. et al. Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson’s syndrome compared with Cushing’s disease. Clin Endocrinol (Oxf) 2004; 60: 765-772
• 72 Nieman LK, Biller BM, Findling JW. et al. The diagnosis of Cushing’s syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 73 Resetić J, Reiner Z, Lüdecke D. et al. The effects of cortisol, 11-epicortisol, and lysine vasopressin on DNA and RNA synthesis in isolated human adrenocorticotropic hormone-secreting pituitary tumor cells. Steroids 1990; 55: 98-100
• 74 Westphal M, Jaquet P, Wilson CB. Long-term culture of human corticotropin-secreting adenomas on extracellular matrix and evaluation of serum-free conditions. Morphological aspects. Acta Neuropathol 1986; 71: 142-149
• 75 Khattak MNK, Buchfelder M, Kleindienst A. et al. CRH and SRIF have opposite effects on the Wnt/β-catenin signalling pathway through PKA/GSK-3β in corticotroph pituitary cells. Cancer Invest 2010; 28: 797-805
• 76 Gertz BJ, Contreras LN, McCOMB DJ. et al. Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number. Endocrinology 1987; 120: 381-388
• 77 Van der Klaauw AA, Kienitz T, Strasburger CJ. et al. Malignant pituitary corticotroph adenomas: Report of two cases and a comprehensive review of the literature. Pituitary 2009; 12: 57-69
• 78 Nagesser SK, van Seters AP, Kievit J. et al. Long-term results of total adrenalectomy for Cushing’s disease. World J Surg 2000; 24: 108-113
• 79 Reincke M, Albani A, Assie G. et al. Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome): Systematic review and expert consensus recommendations. Eur J Endocrinol 2021; 184: P1-P16
• 80 Bahurel-Barrera H, Assie G, Silvera S. et al. Inter- and intra-observer variability in detection and progression assessment with MRI of microadenoma in Cushing’s disease patients followed up after bilateral adrenalectomy. Pituitary 2008; 11: 263-269
• 81 Barnett AH, Livesey JH, Friday K. et al. Comparison of preoperative and postoperative ACTH concentrations after bilateral adrenalectomy in Cushing’s disease. Clin Endocrinol (Oxf) 1983; 18: 301-305
• 82 Jenkins PJ, Trainer PJ, Plowman PN. et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 1995; 80: 165-171
• 83 Kasperlik-Załuska AA, Nielubowicz J, Wisławski J. et al. Nelson’s syndrome: Incidence and prognosis. Clin Endocrinol (Oxf) 1983; 19: 693-698
• 84 Kelly WF, MacFarlane IA, Longson D. et al. Cushing’s disease treated by total adrenalectomy: Long-term observations of 43 patients. Q J Med 1983; 52: 224-231
• 85 Moreira AC, Castro M, Machado HR. Longitudinal evaluation of adrenocorticotrophin and beta-lipotrophin plasma levels following bilateral adrenalectomy in patients with Cushing’s disease. Clin Endocrinol (Oxf) 1993; 39: 91-96
• 86 Pereira AA, Halpern A, Salgado LR. et al. A study of patients with Nelson’s syndrome. Clin Endocrinol (Oxf) 1998; 49: 533-539
• 87 Mauermann WJ, Sheehan JP, Chernavvsky DR. et al. Gamma knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy. J Neurosurg 2007; 106: 988-993
• 88 Marek J, Ježková J, Hána V. et al. Gamma knife radiosurgery for Cushing’s disease and Nelson’s syndrome. Pituitary 2015; 18: 376-384
• 89 Godbout A, Manavela M, Danilowicz K. et al. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol 2010; 163: 709-716
• 90 Burman P, Edén-Engström B, Ekman B. et al. Limited value of cabergoline in Cushing’s disease: A prospective study of a 6-week treatment in 20 patients. Eur J Endocrinol 2016; 174: 17-24
• 91 Ferriere A, Cortet C, Chanson P. et al. Cabergoline for Cushing’s disease: A large retrospective multicenter study. Eur J Endocrinol 2017; 176: 305-314
• 92 Pivonello R, Faggiano A, Di Salle F. et al. Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 1999; 22: 860-865
• 93 Casulari LA, Naves LA, Mello PA. et al. Nelson’s syndrome: Complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004; 62: 300-305
• 94 Shraga-Slutzky I, Shimon I, Weinshtein R. Clinical and biochemical stabilization of Nelson’s syndrome with long-term low-dose cabergoline treatment. Pituitary 2006; 9: 151-154
• 95 Katznelson L. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson’s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. J Clin Endocrinol Metab 2013; 98: 1803-1807
• 96 Daniel E, Debono M, Caunt S. et al. A prospective longitudinal study of Pasireotide in Nelson’s syndrome. Pituitary 2018; 21: 247-255
• 97 Moyes VJ, Alusi G, Sabin HI. et al. Treatment of Nelson’s syndrome with temozolomide. Eur J Endocrinol 2009; 160: 115-119
• 98 Imai T, Funahashi H, Tanaka Y. et al. Adrenalectomy for treatment of Cushing syndrome: Results in 122 patients and long-term follow-up studies. World J Surg 1996; 20: 781-786
• 99 Kemink L, Pieters G, Hermus A. et al. Patient’s age is a simple predictive factor for the development of Nelson’s syndrome after total adrenalectomy for Cushing’s disease. J Clin Endocrinol Metab 1994; 79: 887-889
• 100 Briet C, Salenave S, Bonneville J-F. et al. Pituitary Apoplexy. Endocr Rev 2015; 36: 622-645